Clinical trials: Tamoxifen
Breast Cancer
Decision Aids for Tamoxifen Treatment in Breast Cancer Patients
This is an educational intervention study for breast cancer patients who undergo tamoxifen treatment. The purpose of the study is to assess the impact of decision aids (DA) on the patients' decision-making process, compliance on…
- Trial name
- NCT02488603
- Testing
- Decision aids (tamoxifen-related educational materials in brochure or mobile app), tamoxifen
- Volunteers
- 360 people, healthy volunteers welcome
- Sponsor
- National Cancer Center, Korea
COVID-19
Combination Therapy With Isotretinoin and Tamoxifen Expected to Provide Complete Protection Against Severe Acute Respiratory Syndrome Coronavirus
Combination Therapy with Isotretinoin and Tamoxifen expected to provide Complete Protection against Severe Acute Respiratory Syndrome Coronavirus Abstract: The COVID-19 pandemic caused by SARS-COV-2 has infected over 2,000,000…
- Trial name
- Combination (NCT04389580)
- Testing
- Drug: Isotretinoin plus Tamoxifen, Aerosolized Isotretinoin plus Tamoxifen
- Volunteers
- 160 people
- Sponsor
- Kafrelsheikh University
Breast Cancer
Tamoxifen Citrate Decision Aids for Women at Increased Risk of Breast Cancer
RATIONALE: Evaluating a decision aid that describes the risks and benefits of taking tamoxifen citrate to prevent breast cancer may be helpful for women at increased risk of breast cancer.
- Trial name
- NCT00967824
- Testing
- informational intervention, questionnaire administration, survey administration
- Volunteers
- 1,683 people
- Sponsor
- University of Michigan Rogel Cancer Center
Refusal of Breast Surgery in Patients With Breast Cancer With a cCR After NST and a Confirmed Pathological Complete Response (pCR) Using VAB and SLNB
Refusal of Breast Surgery in Patients With Breast Cancer With a Clinical Complete Response (cCR) After Neoadjuvant Systemic Therapy and a Confirmed Pathological Complete Response (pCR) Using Vacuum-assisted Biopsy (VAB) and Sentinel Lymph Node Biopsy (SLNB)
The main goal of the study is to abandon breast surgery in patients with breast cancer with a clinical complete response (cCR) after neoadjuvant systemic therapy and confirmed pCR using Vacuum-assisted biopsy (VAB) and sentinel…
- Trial name
- VAB (NCT04293796)
- Testing
- Vacuum-assisted biopsy
- Where
- Russia
- Volunteers
- 60 people
- Sponsor
- N.N. Petrov National Medical Research Center of Oncology
Breast Cancer, Osteoporosis
Fingernails in Evaluating Bone Health in Postmenopausal Women With Breast Cancer Undergoing Hormone Therapy on Clinical Trial IBCSG-1-98
RATIONALE: Studying samples of fingernails in the laboratory from patients with breast cancer may help in evaluating bone health in postmenopausal women undergoing hormone therapy for breast cancer.
- Trial name
- NCT00899288
- Testing
- spectroscopy
- Volunteers
- 60 people
- Sponsor
- ETOP IBCSG Partners Foundation
Breast Cancer
Efficacy and Safety of LY01005 in Patients With Breast Cancer Compared to ZOLADEX®
This is a multicenter, randomized, open-label, active comparator-controlled phase Ⅲ trial to compare efficacy and safety of Goserelin Acetate Sustained-Release Microspheres for Injection (LY01005) and ZOLADEX® in patients with…
- Trial name
- NCT05110170
- Testing
- LY01005, ZOLADEX® 3.6 mg
- Where
- China
- Volunteers
- 188 people
- Sponsor
- Luye Pharma Group Ltd.
Breast Cancer
Adjuvant AI Combined With Zoladex
The present study is a randomized open-label -phase III study that aims to compare the efficacy of Zoladex® combined with Aromidex® for 3-2 years after SERMs (tamoxifen and Fareston®) as an adjuvant therapy for 2-3 years with the…
- Trial name
- NCT01352091
- Testing
- Zoladex+AI, TAM
- Where
- China
- Volunteers
- 670 people
- Sponsor
- Fudan University
Estrogen Receptor-negative Breast Cancer, Estrogen Receptor-positive Breast Cancer
Combination Chemotherapy and Filgrastim Before Surgery in Treating Patients With HER2-Positive Breast Cancer That Can Be Removed By Surgery
This phase II trial studies how well giving combination chemotherapy and filgrastim together before surgery works in treating patients with human epidermal growth receptor 2 (HER2)-positive breast cancer that can be removed by…
- Conditions
- Estrogen Receptor-negative Breast Cancer, Estrogen Receptor-positive Breast Cancer, HER2-positive Breast Cancer, Progesterone Receptor-negative Breast Cancer
- Trial name
- NCT00194779
- Testing
- doxorubicin hydrochloride, cyclophosphamide, paclitaxel
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of Washington
Prostate Cancer, Adenocarcinoma of the Prostate
Bicalutamide and Raloxifene in Treating Patients With Metastatic or Hormone-Refractory Prostate Cancer
RATIONALE: Androgens can cause the growth of prostate cancer cells. Antihormone therapy, such as bicalutamide, may lessen the amount of androgens made by the body.
- Conditions
- Prostate Cancer, Adenocarcinoma of the Prostate, Hormone-resistant Prostate Cancer, Stage IV Prostate Cancer
- Trial name
- NCT01050842
- Testing
- bicalutamide, raloxifene, quality-of-life assessment
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Mayo Clinic
Breast Cancer Subjects
Safety, Efficacy and Pharmacokinetic Behavior of Leuprolide Injectable Emulsion for Premenopausal Breast Cancer Subjects.
The study is to assess the safety, efficacy and pharmacokinetic Behavior of Leuprolide Injectable Emulsion for Premenopausal Breast Cancer Subjects.
- Trial name
- NCT06449027
- Testing
- T Leuprolide Injectable Emulsion, Leuprorelin Acetate Microspheres for Injection
- Where
- China
- Volunteers
- 211 people
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
Malignant Tumor, Diarrhea
XCHT for Irinotecan-Induced Gut Toxicities (Run-in Study)
Run-in safety study, to determine the safety of co-administration of irinotecan, raloxifene, and Xiao Chai Hu Tang (XCHT), and to optimize the blood collection time points for pharmacokinetic (PK) study for another randomized…
- Trial name
- NCT04926545
- Testing
- Xiao Chai Hu Tang (XCHT), Raloxifene, FOLFIRI regimen
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Guangzhou University of Traditional Chinese Medicine
Breast Cancer, Stage IV Breast Cancer
Tamoxifen Citrate in Treating Patients With Metastatic or Recurrent Breast Cancer
RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy using tamoxifen citrate may fight cancer by blocking the use of estrogen by tumor cells.
- Trial name
- NCT01124695
- Testing
- tamoxifen
- Where
- 294 sites in United States, Canada and 1 more
- Volunteers
- 124 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Metastatic Breast Cancer
ER Reactivation Therapy for Breast Cancer
Before anti-estrogens such as tamoxifen were developed to treat estrogen receptor (ER)-positive breast cancer, high-dose estrogen therapies were used.
- Trial name
- POLLY (NCT02188745)
- Testing
- 17B-estradiol, Letrozole, Anastrozole
- Where
- 3 sites in United States
- Volunteers
- 20 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Postmenopausal, Metastatic Breast Cancer
A Multicenter Trial Assessing the Efficacy and Safety of tamOxifen Plus LY2228820 in Advanced or Metastatic Breast Cancer Progressing on aromatasE Inhibitors
Metastatic breast cancer (MBC) remains an incurable disease and despite an improvement of the effect of systemic treatments. After relapse on first-line non-steroidal aromatase inhibitor, current clinical practice and treatment…
- Trial name
- OLYMPE (NCT02322853)
- Testing
- Tamoxifen, Ralimetinib (LY2228820 dimesylate)
- Where
- 14 sites in France
- Volunteers
- 8 people
- Sponsor
- Centre Francois Baclesse
Post Menopausal, Breast Cancer
Observational Triveneto Study on the Use of Adjuvant Hormonal Therapies in the Treatment of Hormone-responsive Breast Cancer
There are different types of hormonal therapy medicines for the treatment of hormone-receptor-positive breast cancer. The purpose of this study is to determine the evolution of two types of hormonal treatment (the drug called…
- Trial name
- TIME 2 CHANGE (NCT00884143)
- Where
- 3 sites in Italy
- Volunteers
- 515 people
- Sponsor
- AstraZeneca
Breast Cancer, Chemotherapy
Risk and Clinical Benefit of Chemotherapy and Intensive Endocrine Therapy for Luminal B1 Early-stage Breast Cancer
Breast cancer is the most common female malignancy in the world, and the leading cause of cancer-associated mortalities among women.
- Conditions
- Breast Cancer, Chemotherapy, Endocrine Breast Diseases
- Trial name
- NCT03373708
- Testing
- Epirubicin, Cyclophosphamide, Docetaxel
- Volunteers
- 200 people
- Sponsor
- Zhiyong Yu
CYP2D6 Polymorphism
A Study to Evaluate Exemestane Tablets Combined With Ovarian Function Suppression/Ablation in Treatment of Premenopausal Breast Cancer Patients With CYP2D6*10 Mutations （STEP）
This is a multicenter, randomized, open-label, parallel, active-controlled superiority clinical study conducted in early premenopausal estrogen-receptor positive breast cancer patients with CYP2D6*10 mutations.
- Trial name
- STEP (NCT03137368)
- Testing
- Exemestane Tablets, ovarian function suppression/ablation, CYP2D6*10 gene test
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Breast Cancer
Targeting EGFR/ERBB2 With Neratinib in Hormone Receptor (HR)-Positive/HER2-negative HER2-enriched Advanced/Metastatic Breast Cancer
HR+/HER2-negative BC represent ∼70% of all newly diagnosed breast tumours and are responsible for most recurrences and deaths due to this disease, and despite available standard therapies, ∼15-20% of hormone tumours recur at…
- Trial name
- NEREA (NCT04460430)
- Testing
- Neratinib + endocrine therapy
- Where
- 15 sites in Portugal, Spain
- Volunteers
- 12 people
- Sponsor
- SOLTI Breast Cancer Research Group
Osteoporosis
Study Evaluating Changes In Mammographic Breast Density
The objective of the study is to evaluate quantitative changes in mammographic breast density from baseline to 24 months in postmenopausal women receiving daily doses of either BZA 20 mg/CE 0.45 mg, BZA 20 mg/CE 0.625 mg…
- Trial name
- NCT00774267
- Testing
- BZA 20 mg/CE 0.45 mg, BZA 20 mg/CE 0.625 mg, Raloxifene 60 mg
- Where
- 26 sites in United States, Brazil and 2 more
- Volunteers
- 507 people
- Sponsor
- Pfizer
Breast Cancer
Feasibility Study for the Determination of Oxysterols in Patients With Breast Cancer Receiving Hormonal Therapy With Tamoxifen or Not
This is a biomedical study of interventional type which includes 29 patients on 9 months: 8 months recruiting and 1 month follow up.
- Trial name
- OXYTAM (NCT01553903)
- Testing
- Tamoxifen,, Exemestane, Anastrozole
- Where
- France
- Volunteers
- 29 people
- Sponsor
- Institut Claudius Regaud